MycoLogics, Inc. San Joaquin Valley Fever Vaccine Demonstrates Proof-of-Concept in Animal Model

Thursday, 28 Sep 2006 · Biotechnology

MycoLogics, Inc., today announced that its prophylactic vaccine against coccidioidomycosis, also known as San Joaquin Valley Fever (SJVF), demonstrated statistically significant proof-of-concept results in an animal model assay. (PRWEB Sep 21, 2006) Trackback URI: http://www.prweb.com/zingpr.php/SW5zZS1JbnNlLUluc2UtSG9yci1JbnNlLVplcm8= Read More »

Also:

Colorado Bioscience Association Showcases the State’s Most Promising Technologies
New White Paper Explores the Complexities of Effectively Applying Computer Technologies in a Transgenic Animal Laboratory Research Environment
CXO Advisory Group Teaches Entrepreneurs in Prince Edward Island, Canada ‘How to Build a Bullet-Proof Startup’
New White Paper Explores Basic Problem of How to Effectively Apply Computer Technologies in the Laboratory Research Environment
Ottawa’s Venture and Technology Summit Set to Attract Silicon Valley Investors to Canada’s Capital

del.icio.us · digg it · link

	Vitalea Science Expands its Scientific Advisory Board, Expands Microdosing to Environmental Fate and Metabolism of Agricultural and Industrial Chemicals
	Technology Transfer Firm Partners with Local Alternative Energy Venture to Speed Commercialization: Innovation Management Partners, LLC Invests in Cleveland-based CleanFlo Technologies, LLC to Accelerate Technology Commercialization in the Growth Market for Alternative Fuels
	The AEgis Technologies Group Announces the Release of the Microsoft Excel Add-in for acslXtreme
	Monebo Technologies Obtains FDA Clearance to Market the CardioBelt™ Wireless ECG System
	Five Japanese Pharmaceutical Companies License Ariadne Pathway Studio Enterprise
	Alaska's Natural/Wild Food, Beverage and Bio Products Join Together to Stage Marketplace for Restaurant, Grocery and Food Service Market Buyers
	Akaza Research, SemanticBits and Robert H. Lurie Comprehensive Cancer Center of Northwestern University Partner to Develop caBIG™ Clinical Trials Adverse Events Reporting System for NIH's National Cancer Institute
	Amorcyte Cardiac Cell Therapy Trial Completes Second of Four Phases
	Vitalea Science Announces Key Addition to its Scientific Advisory Board in Microdosing for Pediatric Pharmacology and HIV Research
	Arrowhead Publishers' New Study Reveals Trends in Pharmaceutical Clinical Trial Outsourcing to Emerging Markets

	Biotechnology
	Electronics
	General
	Graphic Design & Printing
	Industrial
	Information Technology
	Instrumentation
	Multimedia
	Nanotechnology
	Public Sector
	Robotics
	Semiconductors
	Telecommunications